Kornimate/medical-research-clean huggingface dataset:
visionaire: a prospective study

Conditions: Osteoarthritis

Summary: the purpose of the current study is to validate the technology of mri-based alignment for total knee replacements and to collect data on potential advantages of the computer aided system. 1. it is hypothesized that there will be no significant differences in position, loosening, or function of the visionaire total knee as compared to the conventional total knee. 2. it is hypothesized that the visionaire total knee will be significantly better with regard to operative time, tourniquet time, blood loss, and procedural set-up, turnover time, and overall costs.


Eligibility criteria:
inclusion criteria: * adult patients with sufficient symptoms from articular knee pathology to be an appropriate candidate for tka exclusion criteria: * prior tka * ipsilateral upper tibial or distal femoral osteotomy * ipsilateral total hip arthroplasty * patient with significant \>15o varus or valgus * morbid obesity or those patients unable to have an mri based on thigh circumference (22 cm or less)

Keywords: total knee arthroplasty (tka) computer aided systems
treatment of language and memory in patients with alzheimer's disease

Conditions: Alzheimer Disease

Summary: the purpose of this study is to collect data on the effects of behavioral interventions for memory and communication deficits in persons taking cholinesterase inhibitors compared with the effects of cholinesterase inhibitors alone. initial testing will include a written case history, tests of communication skills, and interviews with the participants, family, and staff caregivers to help select potential goals for treatment. participants will be randomly selected to participate in group a (control) or group b (intervention). group a will use a caregiver checklist for eight weeks to identify any increase or decrease in the occurrence of the identified communication deficits. group b will have 16 treatment sessions by a speech language pathologist during the eight-week period. a post test will be administered to all participants.

patients with dementia suffer from a variety of cognitive-linguistic deficits, including attention, orientation, memory, anomia, and pragmatics. behavioral treatment of these deficits falls within the domain of speech-language pathology. while no efficacy studies have emerged to demonstrate the benefit of speech-language therapy for individuals who suffer alzheimer's disease (ad), data are emerging which support the positive effects of memory and communication intervention in this population. phase i and phase ii investigations are beginning to provide evidence that such intervention should focus on the development of innovative strategies to help patients compensate for the disabilities resulting from the disease rather than on traditional rehabilitation of impairment. the benefits of cholinesterase inhibitors for improving cognitive function in persons with ad have been demonstrated, and data continue to emerge on specific drugs and specific changes in cognitive processes. the purpose of the proposed investigation would be to collect pilot data on the effects of behavioral intervention for memory and communication deficits in conjunction with cholinesterase inhibitors, as compared with the effects of cholinesterase inhibitors used in isolation. participants will be individuals with ad who are recruited from the alzheimer's disease center at the university of arkasas for medical sciences medical center. all participants will be taking cholinesterase inhibitors, and half of all participants will be randomly selected to receive intervention by a speech-language pathologist. intervention will consist of 16 treatment sessions (one hour each) over a two month period and will focus on strategies for enhancing memory and functional communication.

Eligibility criteria:
inclusion criteria: * alzheimer's disease (middle stage) exclusion criteria: * none

Keywords: alzheimer's disease memory treatment
antiseptic and analgesic action acmella oleracea skin: randomized clinical trial

Conditions: Phythoterapy; Venipuncture Site Numbness; Antimicrobial; Analgesic

Summary: context: research on natural products with therapeutic, analgesic or antimicrobial purpose should be encouraged to create new drugs. acmella oleracea, typical plant of the northern region of the country and popularly known as jambu, has aroused the interest of researchers because of its therapeutic potential. objective: to evaluate the potential topical analgesic and antimicrobial of acmella oleracea plant extract from the skin antisepsis in venipuncture procedures. methods: this is a clinical, randomized, controlled trial with healthy volunteers recruited at the clinic i of the collection of biological materials sector of the hospital das clinicas samuel libânio, in pouso alegre-mg. the plant extract a. oleracea manipulated with transcutol® and 70% alcohol were used in the volunteers before the venipuncture procedure as allocation in study groups. held collection of skin microbiota by the swab technique and the end of the venipuncture procedure was applied to the volunteer, the visual numeric scale (vns) standard to determine the degree of pain.

context: research on natural products with therapeutic, analgesic or antimicrobial purpose should be encouraged to create new drugs. acmella oleracea, typical plant of the northern region of the country and popularly known as jambu, has aroused the interest of researchers because of its therapeutic potential. objective: to evaluate the potential topical analgesic and antimicrobial of acmella oleracea plant extract from the skin antisepsis in venipuncture procedures. methods: this is a clinical, randomized, controlled trial with healthy volunteers recruited at the clinic i of the collection of biological materials sector of the hospital das clinicas samuel libânio, in pouso alegre-mg. the plant extract a. oleracea manipulated with transcutol® and 70% alcohol were used in the volunteers before the venipuncture procedure as allocation in study groups. held collection of skin microbiota by the swab technique and the end of the venipuncture procedure was applied to the volunteer, the visual numeric scale (vns) standard to determine the degree of pain.

Eligibility criteria:
inclusion criteria: * healthy volunteers * without restriction as to ethnicity * educational level and social class who agreed to participate by signing the informed consent and informed (ic ) exclusion criteria: * pregnant women (due to contractile properties that can cause ) * cancer patients * chronic and refusal to participate in the study kidney

Keywords: analgesic medicinal plants skin antimicrobial agents pain measurement
is second knee at risk during simultaneous bilateral total knee arthroplasty.

Conditions: Osteoarthritis, Knee; Infection; Periprosthetic Fracture Around Prosthetic Joint Implant

Summary: the effects of single-team simultaneous bilateral total knee arthroplasty on peri- and postoperative complications are clear. the investigators hypothesized that second knee at risk during single-team simultaneous bilateral total knee arthroplasty and have more early postoperative complication rates than the first knee. therefore, this prospective study compared minor and major local complications for 90 days postoperatively between the first and second during knee single-team simultaneous bilateral total knee arthroplasty.

the investigators would like to compare operation related technical complications and periprosthetic joint infection rate between the first and second knee.

Eligibility criteria:
inclusion criteria: * primary bilateral knee osteoarthritis with refractory to conservative treatment * patients who accept participation in the research and the randomization exclusion criteria: * no history of malignancy * less than 75 years old * severe cardiac insufficiency and morbid obesity
breaks in sedentary time and glucose regulation in women

Conditions: Impaired Glucose Tolerance

Summary: the number of people diagnosed with type 2 diabetes (t2dm) is increasing rapidly and about 2.9 million people in the uk currently have diabetes. there is increasing evidence suggesting that prolonged sedentary time may actually increase the risk of diabetes and other chronic diseases. importantly, adults can meet public health guidelines on physical activity (150 minutes of moderate activity per week), but if they still sit for prolonged periods, their metabolic health is compromised. going from sitting to standing and carrying out light-intensity activities (such as casual walking) may reduce diabetes risk. however, no one has investigated the effect of standing and walking on markers of cardio-metabolic markers in individuals with a high risk of t2dm. therefore, the aim is to find out whether reducing the amount of time people spend sitting and replacing it with standing and light intensity activity (walking) reduces glucose, insulin and triglyceride levels, therefore reducing the risk of diabetes.


Eligibility criteria:
inclusion criteria: * sedentary * overweight or obese (bmi\>25kg/m2) * post menopausal * previous diagnosis of impaired glucose tolerance exclusion criteria: * regular purposeful exercise (≥150 minutes of mvpa per week) * physical condition which limits full participation in the study * active psychotic illness or other significant illness which, in the view of the investigators, would prevent full participation * inability to communicate in spoken english * steroid use * known type 2 diabetes * pregnancy * male * currently taking hormone replacement medication.
multiparametric magnetic resonance imaging (mri) to improve bladder cancer staging and treatment decision-making

Conditions: Bladder Cancer

Summary: the therapeutic approach to bladder cancer is strongly dependent on tumor stage and grade. patients with non-muscle-invasive tumors (nmibc) are usually treated with surgical resection of the tumor alone, whereas patients with muscle-invasive tumors (mibc) ideally undergo neoadjuvant chemotherapy (nct) and subsequent cystectomy. magnetic resonance imaging (mri) is emerging as a new staging modality, given its non-invasiveness and excellent soft tissue contrast. however, more advanced multiparametric mri techniques are yet to be comprehensively investigated in patients with bladder cancer. recently, genetic characteristics of bladder tumors have been identified that show significant impact on response rates to neoadjuvant treatment. the combination of new multiparametric mri (mpmri) techniques and genetic analyses of the tumor might allow for a better assessment of the expected clinical course of the disease and support more personalized treatment approaches.


Eligibility criteria:
inclusion criteria: * patients with confirmed or suspected primary bladder cancer and a circumscribed tumor/focal thickening of the bladder wall on initial imaging (ultrasound, ct) or cystoscopy with an approx. size of ≥ 1.5 cm/for which at least 2-3 tur-b resection loops are necessary * informed consent as documented by signature (informed consent form) exclusion criteria: * prior tur-b or other bladder treatment, prior treated bladder cancers, prior pelvic irradiation * women who are pregnant or breast-feeding. female participants who are surgically sterilized / hysterectomized or post-menopausal for longer than 2 years are not considered as being of childbearing potential. * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant * previous enrolment into the current study * patients with non-mri compatible metallic or electronic implants, devices or metallic foreign bodies (cardiac pacemaker, shrapnel, cochlea implants, neurostimulator, or other non-mri compatible implants).
analysis of genes present in cutaneous t-cell lymphoma cells

Conditions: Lymphoma

Summary: rationale: analyzing genes that are present in cancer cells may be useful in developing better methods to detect, predict, and treat cutaneous t-cell lymphoma. purpose: clinical trial to study genes that are present in cutaneous t-cell lymphoma cells.

objectives: * identify gene expression patterns in malignant t cells that can be used to diagnose cutaneous t-cell lymphoma. * determine the patterns of gene expression that distinguish normal skin-homing t cells from malignant t cells. outline: patients are stratified by disease (sezary syndrome vs mycosis fungoides) and prior treatment (yes vs no). all patients receive a physical examination, and a medical history is taken. patients with sezary syndrome undergo leukapheresis. patients with plaque/tumor stage mycosis fungoides undergo skin biopsy of involved skin. malignant t cells from blood or skin are then isolated and patterns of gene expression in the malignant t cells are compared to those in normal skin-homing t cells from healthy donors using a "gene chip" (lymphochip). patients are followed annually for 5 years. projected accrual: a total of 40 patients (20 per disease stratum) will be accrued for this study within 2 years.

Eligibility criteria:
disease characteristics: * histologically proven mycosis fungoides with 2 or more plaques or tumors greater than 1 cm in size or * immunologically proven sezary syndrome with all of the following: * erythroderma * lymphadenopathy * t-cell receptor variable beta chain clonality greater than 10% of total lymphocytes by flow cytometry or * cd4+cd7- t-cell fraction that represents greater than 10% of cd4+ t cells patient characteristics: age: * 18 to 85 performance status: * not specified life expectancy: * not specified hematopoietic: * see disease characteristics hepatic: * not specified renal: * not specified other: * not pregnant or nursing * hiv-1 and htlv-1 negative * no prior intravenous drug use prior concurrent therapy: biologic therapy: * not specified chemotherapy: * at least 2 months since prior systemic chemotherapy endocrine therapy: * not specified radiotherapy: * at least 2 months since prior electron beam radiotherapy surgery: * not specified other: * at least 2 weeks since prior topical therapy * at least 2 months since prior photopheresis * at least 2 months since prior psoralen ultraviolet light (puva) or ultraviolet b (uvb) therapy

Keywords: cutaneous t-cell non-hodgkin lymphoma mycosis fungoides/sezary syndrome
apa on sleep quality in women with pcos

Conditions: Polycystic Ovary Syndrome

Summary: women with polycystic ovary syndrome (pcos) appear to have an increased frequency of sleep problems. the aim of this study was to explore the effect of auricular point acupressure (apa) pressure on sleep quality in women with pcos.

polycystic ovary syndrome (pcos) is a prevalent disorder affecting 5-18% of reproductive-age women. in recent years, women with pcos appear to have an increased frequency of sleep problems, and the prevalence of poor sleep in pcos is high at 31%. the aim of this study was to explore the effect of auricular point acupressure (apa) pressure on sleep quality in women with pcos. we verified the effect of apa pressure on sleep quality, quality of life, anxiety level, sex hormone indexes, and biochemical indexes in two groups after the intervention. so as to provide a sleep management strategy in pcos women for future clinical practice guidelines.

Eligibility criteria:
subjects were included if they 1. were aged between 18-40 years old; 2. met the clinical diagnostic criteria of western and chinese medicine for pcos with sleep disorders; 3. were evaluated by the pittsburgh sleep quality index scale (psqi) and had a score ≥ 7 points; 4. did not participate in other clinical trials. subjects were excluded if they 1. had a serious organic condition such as cardiovascular, cerebrovascular, liver, or kidney disease; 2. had acute gynecological inflammation, gynecological tumors, or reproductive system malformations; 3. had severe anxiety, depression, or other mental illnesses; 4. were pregnant; 5. had used sleeping and sedative drugs in the past month; 6. were allergic to ear point tape; 7. had local rupture of the skin at the selected ear point; 8. refused to fill out questionnaires and sign informed consent forms.
set-up of a platform for personalized diagnosis of rare kidney diseases (nike)

Conditions: Chronic Kidney Diseases

Summary: chronic kidney disease (ckd) is a major health problem, with steadily increasing incidence and prevalence and the threat of a true "epidemic". converging evidence suggests a high prevalence of genetic etiology in rare kidney diseases and the list of new disease-causing genes is constantly updated. recent advances in next-generation sequencing (ngs) technologies have prompted a significant improvement in the diagnosis of rare kidney diseases. notwithstanding this, ngs generates high numbers of information that need to be properly analysed by the joint efforts of geneticists, nephrologists and bioinformatics in order to integrate clinical and genetic information in a personalized manner. in addition, in selected cases, the contribution of researchers proves essential for the development of experimental models of the disease to study and understand the pathogenic features and propose a personalized therapeutic approach. such an innovative, integrated diagnostic paradigm is currently available in few centers all over the world and cannot be easily translated in daily clinical practice. the aim of the study is to set-up an integrated diagnostic algorithm to extend the newest personalized diagnostic and treatment strategies for rare kidney diseases to all patients in the tuscany region, under 40 years of age with kidney disease. this algorithm will be based on a constant cross-talk between participating centers and a dedicated multidisciplinary team. diagnostic and therapeutic performances will be validated at european level.


Eligibility criteria:
inclusion criteria: * family history of kidney disease and/or parental consanguinity; * extra-renal involvement (e.g., sensorineural hearing loss); * resistance to treatment (e.g., immunosuppressive); * metabolic acidosis or metabolic alkalosis in the absence of renal failure; * ultrasound detection of of at least 2 cystic lesions in each kidney or nephrocalcinosis; * ultrasound detection of congenital abnormalities of the kidney and urinary tract (cakut) and ckd stage ≥ 2 according to kdigo definition * informed consent form. exclusion criteria: * age \> 40 * refuse to participate to the study
study evaluating venlafaxine er in patients with panic disorder

Conditions: Panic Disorder

Summary: the primary objective is to determine the efficacy, safety, and tolerability of venlafaxine extended release (er) capsules in the treatment of outpatients with panic disorder (pd) in comparison to those of placebo.


Eligibility criteria:
inclusion criteria: * meet dsm-iv criteria for pd (with or without agoraphobia) for at least 3 months before study day 1 * have sufficient symptoms to require anxiolytic drug therapy * have a score ≥4 on the clinical global impressions scale (cgi) severity of illness item at screening and baseline exclusion criteria: * known hypersensitivity to venlafaxine (ir or er), related compounds, or paroxetine * history or presence of any clinically important hepatic, renal, or other medical disease that might compromise the study or be detrimental to the patient (eg, clinically important cardiac arrhythmia, unstable diabetes, carcinoma \[except basal cell epithelioma\], uncontrolled hypertension) * clinically important abnormality on screening physical examination, vital signs, electrocardiogram (ecg), laboratory tests or urine drug screen

Keywords: panic disorder
identifying underserved individuals intexas with hereditary cancer risk using mobile mammography units and telegenetics.

Conditions: Ovarian Cancer; Breast Cancer; Colorectal Cancer

Summary: identifying women at risk for hereditary cancer potentiates prevention, early detection or personalised treatment against cancer. we using mobile mammography units will provide genetic sceening and testing services to underserved women coming for thier mammograms to these units.

objectives: 1. to identify underserved women at risk for hereditary breast and colorectal cancers and would be eligible for standard of care genetic counseling and testing using national screening guidelines. 2. to provide education to providers and patients regarding hereditary cancers using previously irb approved educational material and short video.

Eligibility criteria:
inclusion criteria: any woman scheduled at project valet mammography screening mobile units will be eligible for this study. exclusion criteria:
collection of blood samples from hiv infected people

Conditions: HIV Infections

Summary: the purpose of this study is to collect blood samples from hiv infected individuals for use in future genetic studies.

genetic differences among people with hiv may account for differences in disease progression and response to antiretroviral therapy. the terry beirn community programs for clinical research on aids (cpcra) was created to conduct studies in hiv infected communities and particularly in people of color, women, and injection drug users. this study will collect whole blood samples from hiv infected individuals. the samples will be used in future cpcra studies comparing human genetic factors with clinical data from other cpcra studies.

Eligibility criteria:
inclusion criteria: * presently participating, previously participated in, or has given informed consent for participation in a qualifying cpcra clinical trial * signed informed consent

Keywords: genetic testing genomics human genetic factors
kebele elimination of trachoma for ocular health

Conditions: Trachoma

Summary: the investigators propose a cluster-randomized clinical trial to determine whether an intensive, targeted azithromycin distribution strategy is effective for elimination of trachoma at the kebele level compared to the world health organization (who) recommendation of annual azithromycin distribution.

the investigators propose to randomize at the kebele level, which consist of approximately 15 villages, 4,000 residents, and are served by a single primary school. eighty kebeles will be randomized to one of four arms: 1) annual mass azithromycin distribution per who guidelines (annual); 2) annual mass azithromycin distribution plus quarterly targeted treatment of all children aged 0-9 years (core group-age); 3) annual mass azithromycin distribution plus quarterly targeted treatment of all children aged 0-9 years with a positive chlamydial pcr test (core group-pcr); or 4) annual mass azithromycin distribution plus quarterly targeted treatment of all children aged 0-9 years positive for conjunctival inflammation as assessed from annual photography (core group-ti). the primary outcome for the trial will be the ocular chlamydia prevalence at 12, 24, and 36 months. secondary outcomes will include bacterial load of ocular chlamydia via quantitative pcr, the prevalence of clinically active trachoma assessed at 12, 24, and 36 months, and serology via dried blood spot at baseline and 36 months.

Eligibility criteria:
inclusion criteria: * all individuals in all communities will be eligible for annual mass azithromycin distribution per who guidelines. exclusion criteria: * those who do not consent.

Keywords: azithromycin mass drug administration antibiotic resistance